Bioblast Pharma Ltd. extended the 2014 initial public offering (IPO) window, filing an F-1 with the SEC seeking to raise up to $37.5 million and a listing on the Nasdaq Capital Market. The Tel Aviv firm filed as an emerging growth company under the Jumpstart Our Business Startups Act of 2012.